Abstract 2099: Model-driven optimization of anti-angiogenics combined with chemotherapy: application to bevacizumab + pemetrexed/cisplatin doublet in NSCLC-bearing mice
CICCOLINI, Joseph
Simulation & Modelling : Adaptive Response for Therapeutics in Cancer [SMARTc unit]
Simulation & Modelling : Adaptive Response for Therapeutics in Cancer [SMARTc unit]
BENZEKRY, Sebastien
Modélisation Mathématique pour l'Oncologie [MONC]
Institut de Mathématiques de Bordeaux [IMB]
Modélisation Mathématique pour l'Oncologie [MONC]
Institut de Mathématiques de Bordeaux [IMB]
GIACOMETTI, Sarah
Simulation & Modelling : Adaptive Response for Therapeutics in Cancer [SMARTc unit]
See more >
Simulation & Modelling : Adaptive Response for Therapeutics in Cancer [SMARTc unit]
CICCOLINI, Joseph
Simulation & Modelling : Adaptive Response for Therapeutics in Cancer [SMARTc unit]
Simulation & Modelling : Adaptive Response for Therapeutics in Cancer [SMARTc unit]
BENZEKRY, Sebastien
Modélisation Mathématique pour l'Oncologie [MONC]
Institut de Mathématiques de Bordeaux [IMB]
Modélisation Mathématique pour l'Oncologie [MONC]
Institut de Mathématiques de Bordeaux [IMB]
GIACOMETTI, Sarah
Simulation & Modelling : Adaptive Response for Therapeutics in Cancer [SMARTc unit]
Simulation & Modelling : Adaptive Response for Therapeutics in Cancer [SMARTc unit]
BARLESI, Fabrice
Service d'oncologie multidisciplinaire innovations thérapeutiques [Hôpital Nord - APHM]
Service d'oncologie multidisciplinaire innovations thérapeutiques [Hôpital Nord - APHM]
BARBOLOSI, Dominique
Simulation & Modelling : Adaptive Response for Therapeutics in Cancer [SMARTc unit]
< Reduce
Simulation & Modelling : Adaptive Response for Therapeutics in Cancer [SMARTc unit]
Language
en
Communication dans un congrès
This item was published in
107th Annual Meeting of the American Association for Cancer Research, 2016, New Orleans. vol. 76, n° 14 Supplement, p. 20
Origin
Hal imported